pimozide has been researched along with cyclin d1 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Cui, Y; Fan, Y; Han, W; He, Q; Hu, S; Jin, J; Li, J; Liu, J; Liu, L; Lv, T; Sun, Y; Yang, Y; Yu, W | 1 |
Deng, Q; Li, Z; Liang, J; Liu, Z; Shao, Z; Song, C; Wang, X; Xiao, Z; Yang, X; Zhang, K | 1 |
2 other study(ies) available for pimozide and cyclin d1
Article | Year |
---|---|
CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.
Topics: CD8-Positive T-Lymphocytes; Cell Line; Cell Proliferation; Chemokine CCL5; Coculture Techniques; Cyclin D1; Dihydrotestosterone; Epithelial Cells; Finasteride; Gene Expression Regulation; Humans; Male; Phosphorylation; Pimozide; Prostatic Hyperplasia; Signal Transduction; STAT5 Transcription Factor | 2017 |
Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Topics: Animals; bcl-X Protein; Bromocriptine; Cell Line, Tumor; Cyclin D1; Humans; Mice; Mice, Nude; Pimozide; Pituitary Neoplasms; Prolactinoma; Rats; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |